A detailed history of Parkside Financial Bank & Trust transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Parkside Financial Bank & Trust holds 195 shares of REGN stock, worth $136,860. This represents 0.03% of its overall portfolio holdings.

Number of Shares
195
Previous 191 2.09%
Holding current value
$136,860
Previous $200,000 2.0%
% of portfolio
0.03%
Previous 0.03%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$1024.09 - $1201.76 $4,096 - $4,807
4 Added 2.09%
195 $204,000
Q2 2024

Aug 05, 2024

BUY
$883.2 - $1071.19 $1,766 - $2,142
2 Added 1.06%
191 $200,000
Q1 2024

May 01, 2024

BUY
$902.69 - $993.35 $1,805 - $1,986
2 Added 1.07%
189 $181,000
Q4 2023

Feb 01, 2024

BUY
$775.18 - $881.7 $19,379 - $22,042
25 Added 15.43%
187 $164,000
Q3 2023

Nov 13, 2023

BUY
$692.45 - $844.37 $11,079 - $13,509
16 Added 10.96%
162 $133,000
Q2 2023

Aug 15, 2023

BUY
$700.03 - $830.35 $5,600 - $6,642
8 Added 5.8%
146 $104,000
Q1 2023

May 04, 2023

BUY
$680.49 - $826.97 $10,887 - $13,231
16 Added 13.11%
138 $113,000
Q4 2022

Feb 13, 2023

BUY
$705.89 - $766.39 $12,000 - $13,028
17 Added 16.19%
122 $88,000
Q3 2022

Nov 01, 2022

BUY
$573.97 - $724.32 $16,071 - $20,280
28 Added 36.36%
105 $73,000
Q2 2022

Jul 13, 2022

SELL
$548.35 - $738.84 $10,418 - $14,037
-19 Reduced 19.79%
77 $46,000
Q1 2022

May 13, 2022

BUY
$595.12 - $698.43 $8,331 - $9,778
14 Added 17.07%
96 $67,000
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $4,891 - $6,038
9 Added 12.33%
82 $52,000
Q3 2021

Oct 29, 2021

BUY
$574.03 - $680.96 $6,314 - $7,490
11 Added 17.74%
73 $44,000
Q2 2021

Aug 06, 2021

BUY
$472.8 - $558.54 $5,673 - $6,702
12 Added 24.0%
62 $35,000
Q1 2021

May 10, 2021

SELL
$446.73 - $548.2 $23,676 - $29,054
-53 Reduced 51.46%
50 $24,000
Q4 2020

Feb 09, 2021

BUY
$478.3 - $607.98 $22,001 - $27,967
46 Added 80.7%
103 $50,000
Q3 2020

Nov 06, 2020

BUY
$544.75 - $658.21 $544 - $658
1 Added 1.79%
57 $32,000
Q2 2020

Aug 10, 2020

SELL
$493.32 - $643.92 $2,959 - $3,863
-6 Reduced 9.68%
56 $35,000
Q1 2020

May 05, 2020

BUY
$336.18 - $494.43 $6,387 - $9,394
19 Added 44.19%
62 $30,000
Q4 2019

Jan 30, 2020

BUY
$274.13 - $376.51 $5,482 - $7,530
20 Added 86.96%
43 $17,000
Q3 2019

Nov 05, 2019

BUY
$273.46 - $318.39 $2,187 - $2,547
8 Added 53.33%
23 $6,000
Q2 2019

Aug 06, 2019

SELL
$299.6 - $414.82 $12,283 - $17,007
-41 Reduced 73.21%
15 $5,000
Q1 2019

May 01, 2019

BUY
$372.08 - $439.57 $4,092 - $4,835
11 Added 24.44%
56 $23,000
Q4 2018

Jan 31, 2019

BUY
$335.82 - $403.04 $10,074 - $12,091
30 Added 200.0%
45 $17,000
Q3 2018

Oct 12, 2018

BUY
$351.14 - $408.51 $1,053 - $1,225
3 Added 25.0%
15 $6,000
Q2 2018

Aug 03, 2018

SELL
$284.6 - $344.99 $8,822 - $10,694
-31 Reduced 72.09%
12 $4,000
Q1 2018

May 02, 2018

BUY
$315.82 - $393.78 $5,368 - $6,694
17 Added 65.38%
43 $15,000
Q4 2017

Feb 05, 2018

SELL
$358.63 - $469.95 $1,075 - $1,409
-3 Reduced 10.34%
26 $9,000
Q3 2017

Oct 27, 2017

BUY
$431.38 - $504.0 $12,510 - $14,616
29
29 $13,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $75.2B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.